OPHD 001

Drug Profile

OPHD 001

Alternative Names: Clostridium difficile antibodies - Promega

Latest Information Update: 22 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Promega Corporation
  • Class Antibacterials; Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium-difficile-infections

Most Recent Events

  • 08 Jun 2000 Ophidian has suspended research and product development operations
  • 08 Jun 2000 Suspended-I for Clostridium difficile infections in USA (PO)
  • 11 Jun 1999 OPHD 001 has been named as Ophidian Pharmaceuticals' lead drug candidate for the treatment of Clostridium difficile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top